TY - JOUR
T1 - Medication related osteonecrosis of jaw in a leukemia patient undergoing systemic arsenic trioxide therapy
T2 - A rare case report
AU - Kumar, Mathangi
AU - Vineetha, Ravindranath
AU - Kudva, Adarsh
N1 - Publisher Copyright:
© 2019 Elsevier Ltd
PY - 2019/12
Y1 - 2019/12
N2 - Osteonecrosis of the jaw is a potential side effect of certain pharmaceutical agents used in the field of medicine. Early diagnosis and effective management of this condition can be challenging to the clinicians. Bisphosphonates and other anti-angiogenic agents are the most common drugs that are attributed to cause medication-related osteonecrosis of the jaw. In the past, arsenic-based compounds were commonly used local agents for pulp devitalization therapy. Arsenic is also one of the components of the chemotherapeutic regimen in the management of refractory leukemia. Although local diffusion of the arsenic compounds is known to cause osteonecrosis, there are no reports of the same caused by its systemic administration. Here, we present the first ever case of mandibular bone necrosis in a patient with acute promyelocytic leukemia who underwent systemic arsenic trioxide therapy.
AB - Osteonecrosis of the jaw is a potential side effect of certain pharmaceutical agents used in the field of medicine. Early diagnosis and effective management of this condition can be challenging to the clinicians. Bisphosphonates and other anti-angiogenic agents are the most common drugs that are attributed to cause medication-related osteonecrosis of the jaw. In the past, arsenic-based compounds were commonly used local agents for pulp devitalization therapy. Arsenic is also one of the components of the chemotherapeutic regimen in the management of refractory leukemia. Although local diffusion of the arsenic compounds is known to cause osteonecrosis, there are no reports of the same caused by its systemic administration. Here, we present the first ever case of mandibular bone necrosis in a patient with acute promyelocytic leukemia who underwent systemic arsenic trioxide therapy.
UR - https://www.scopus.com/pages/publications/85076347141
UR - https://www.scopus.com/pages/publications/85076347141#tab=citedBy
U2 - 10.1016/j.oraloncology.2019.06.024
DO - 10.1016/j.oraloncology.2019.06.024
M3 - Letter
C2 - 31255529
AN - SCOPUS:85076347141
SN - 1368-8375
VL - 99
JO - Oral Oncology
JF - Oral Oncology
M1 - 104343
ER -
